Titre : | Should doctors prescribe cannabinoids? (2014) |
Auteurs : | M. FARRELL ; R. BUCHBINDER ; W. HALL |
Type de document : | Article : Périodique |
Dans : | British Medical Journal (Vol.348, n°7956, 3 May 2014) |
Article en page(s) : | g2737 ; 5 p. |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés CANNABINOIDES ; USAGE THERAPEUTIQUE ; PRESCRIPTION MEDICALE ; MECANISME D'ACTION ; DOULEUR ; EFFET SECONDAIRE |
Résumé : | The medical use of cannabis was advocated in the United States in the 1970s and 1980s when clinical trials of oral synthetic tetrahydrocannabinol (THC) and other oral synthetic cannabinoids reported efficacy in controlling nausea in patients with cancer who were undergoing chemotherapy. Dronabinol (an oral synthetic THC) was approved by the Food and Drug Administration in 1985 for this indication, but it was not widely used because patients were unable to titrate doses or disliked its psychoactive effects. It is still available in the US, United Kingdom, and the rest of Europe. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 37 |
Affiliation : | National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2031, Australia |
Accueil